Kholoud Porter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6810366/publications.pdf

Version: 2024-02-01

140 papers	7,582 citations	50170 46 h-index	58464 82 g-index
144 all docs	144 docs citations	144 times ranked	8095 citing authors

#	Article	IF	Citations
1	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. Aids, 2014, 28, 1193-1202.	1.0	453
2	Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. JAMA - Journal of the American Medical Association, 2008, 300, 51.	3.8	404
3	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	4.6	345
4	Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet, The, 2003, 362, 1267-1274.	6.3	336
5	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ: British Medical Journal, 2011, 343, d6016-d6016.	2.4	282
6	Beyond viral suppression of HIV â€“ the new quality of life frontier. BMC Medicine, 2016, 14, 94.	2.3	279
7	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. Aids, 2009, 23, 1743-1753.	1.0	200
8	Short-Course Antiretroviral Therapy in Primary HIV Infection. New England Journal of Medicine, 2013, 368, 207-217.	13.9	194
9	Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. Aids, 2006, 20, 741-749.	1.0	193
10	Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473.	1.0	188
11	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm3: Assessment of Need Following Changes in Treatment Guidelines. Clinical Infectious Diseases, 2011, 53, 817-825.	2.9	180
12	Changes in the incidence and predictors of human immunodeficiency virusâ€“associated dementia in the era of highly active antiretroviral therapy. Annals of Neurology, 2008, 63, 213-221.	2.8	167
13	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
14	Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. Aids, 2005, 19, 487-494.	1.0	120
15	The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Aids, 2011, 25, 1083-1091.	1.0	120
16	Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion. Journal of the National Cancer Institute, 2010, 102, 784-792.	3.0	111
17	Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversion. Archives of Internal Medicine, 2012, 172, 1252.	4.3	102
18	The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. Aids, 2006, 20, 21-28.	1.0	92

#	Article	IF	Citations
19	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	2.9	88
20	Current CD4 Cell Count and the Shortâ€Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIVâ€Infected Children and Adults. Journal of Infectious Diseases, 2008, 197, 398-404.	1.9	87
21	Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. Aids, 2005, 19, 2001-2007.	1.0	85
22	A systematic review of definitions of extreme phenotypes of HIV control and progression. Aids, 2014, 28, 149-162.	1.0	83
23	Gender Differences in HIV Progression to AIDS and Death in Industrialized Countries: Slower Disease Progression Following HIV Seroconversion in Women. American Journal of Epidemiology, 2008, 168, 532-540.	1.6	82
24	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per Î¼L in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-345.	6.3	82
25	CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica, 2009, 94, 875-880.	1.7	81
26	An Evaluation of HIV Elite Controller Definitions within a Large Seroconverter Cohort Collaboration. PLoS ONE, 2014, 9, e86719.	1.1	80
27	Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997. Gastroenterology, 2013, 144, 751-760.e2.	0.6	76
28	Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. Aids, 2007, 21, 1717-1721.	1.0	75
29	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. American Journal of Epidemiology, 2019, 188, 1569-1577.	1.6	75
30	Late Presenters in an HIV Surveillance System in Italy During the Period 1992-2006. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 282-286.	0.9	74
31	Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy. PLoS ONE, 2013, 8, e78287.	1.1	74
32	Late diagnosis in the HAART era: proposed common definitions and associations with mortality. Aids, 2010, 24, 723-727.	1.0	72
33	Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 505-511.	0.9	69
34	Constructing the cascade of HIV care. Current Opinion in HIV and AIDS, 2016, 11, 102-108.	1.5	65
35	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. International Journal of Epidemiology, 2002, 31, 951-958.	0.9	64
36	Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. Virus Evolution, 2018, 4, vey007.	2.2	64

#	Article	IF	Citations
37	Highly Active Antiretroviral Therapy Interruption. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 554-561.	0.9	62
38	Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection. PLoS ONE, 2012, 7, e43754.	1.1	60
39	From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. Lancet HIV,the, 2017, 4, e223-e230.	2.1	59
40	Reorienting health systems to care for people with HIV beyond viral suppression. Lancet HIV,the, 2019, 6, e869-e877.	2.1	57
41	Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. Aids, 2004, 18, 1697-1705.	1.0	56
42	Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990â€“2014. Journal of Hepatology, 2017, 67, 255-262.	1.8	56
43	Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapyâ€”The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. PLoS Medicine, 2010, 7, e1000239.	3.9	54
44	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases, 2019, 69, 2218-2227.	2.9	52
45	The empirical evidence for the impact of HIV on adult mortality in the developing world. Aids, 2004, 18, S9-S17.	1.0	51
46	Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. Aids, 2017, 31, 477-484.	1.0	51
47	CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. Frontiers in Immunology, 2018, 9, 928.	2.2	50
48	Rate of CD4 Decline and HIV-RNA Change Following HIV Seroconversion in Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 441-446.	0.9	48
49	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. Clinical Infectious Diseases, 2017, 64, 1644-1656.	2.9	46
50	Temporal Trends in Postseroconversion CD4 Cell Count and HIV Load: The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985â€“2002. Journal of Infectious Diseases, 2007, 195, 525-534.	1.9	44
51	Natural history of HIV-control since seroconversion. Aids, 2013, 27, 2451-2460.	1.0	44
52	Survival following HIV infection of a cohort followed up from seroconversion in the UK. Aids, 2008, 22, 89-95.	1.0	41
53	A highly virulent variant of HIV-1 circulating in the Netherlands. Science, 2022, 375, 540-545.	6.0	39
54	Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. Aids, 2011, 25, 1395-1403.	1.0	38

#	Article	IF	Citations
55	Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 69-73.	0.9	38
56	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. PLoS Biology, 2017, 15, e2001855.	2.6	38
57	Phylogenetic Reconstruction of Transmission Events from Individuals with Acute HIV Infection: Toward Moreâ€Rigorous Epidemiological Definitions. Journal of Infectious Diseases, 2009, 199, 427-431.	1.9	36
58	Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion. Aids, 2004, 18, 673-681.	1.0	35
59	The Rate of Viral Rebound after Attainment of an HIV Load <50 Copies/mL According to Specific Antiretroviral Drugs in Use: Results from a Multicenter Cohort Study. Journal of Infectious Diseases, 2005, 192, 1387-1397.	1.9	35
60	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. Lancet HIV,the, 2018, 5, e301-e308.	2.1	34
61	The practical significance of potential biases in estimates of the AIDS incubation period distribution _in the UK Register of HIV Seroconverters. Aids, 1999, 13, 1943-1951.	1.0	33
62	Antiretroviral treatment of primary HIV infection to reduce onward transmission. Current Opinion in HIV and AIDS, 2010, 5, 283-290.	1.5	32
63	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. Lancet HIV,the, 2014, 1, e119-e126.	2.1	32
64	Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 126-133.	0.9	32
65	Detection of drug resistance associated mutations in HIV primary infection within the UK. Aids, 2000, 14, 906.	1.0	32
66	Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. Aids, 2004, 18, 1471-1473.	1.0	30
67	Differences in HIV Natural History among African and Non-African Seroconverters in Europe and Seroconverters in Sub-Saharan Africa. PLoS ONE, 2012, 7, e32369.	1.1	30
68	Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. Aids, 2014, 28, 869-874.	1.0	30
69	Primary HIV infection: to treat or not to treat?. Current Opinion in Infectious Diseases, 2008, 21, 4-10.	1.3	29
70	CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. Aids, 2010, 24, 2697-2704.	1.0	29
71	Substantial Heterogeneity in Progress Toward Reaching the 90-90-90 HIV Target in the WHO European Region. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 28-37.	0.9	29
72	Increasing incidence of cryptococcosis in the United Kingdom. Journal of Infection, 1993, 27, 185-191.	1.7	28

#	Article	IF	Citations
73	HIV-1-specific CD4 + responses in primary HIV-1 infection predict disease progression. Aids, 2014, 28, 699-708.	1.0	27
74	Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. Aids, 2007, 21, 1283-1291.	1.0	26
75	The effect of antiretroviral treatment of different durations in primary HIV infection. Aids, 2008, 22, 2441-2450.	1.0	26
76	Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 2013, 68, 207-213.	2.7	26
77	The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART). Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 633-639.	0.9	25
78	Effect of Transient Antiretroviral Treatment during acute HIV Infection: Comparison of the Quest Trial Results with CASCADE Natural History Study. Antiviral Therapy, 2007, 12, 189-194.	0.6	24
79	Short-Term CD4 Cell Response After Highly Active Antiretroviral Therapy Initiated at Different Times From Seroconversion in 1500 Seroconverters. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 303-310.	0.9	22
80	Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. Journal of Clinical Epidemiology, 2005, 58, 1033-1041.	2.4	21
81	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. Aids, 2015, 29, 2323-2333.	1.0	21
82	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. Journal of Infectious Diseases, 2017, 216, 1063-1069.	1.9	20
83	Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection. Aids, 2012, 26, 887-890.	1.0	19
84	Towards standardized definitions for monitoring the continuum of HIV care in Europe. Aids, 2017, 31, 2053-2058.	1.0	19
85	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. Aids, 2018, 32, 161-169.	1.0	19
86	Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. Aids, 2008, 22, 349-356.	1.0	18
87	High Percentage of Recent HIV Infection Among HIV-Positive Individuals Newly Diagnosed at Voluntary Counseling and Testing Sites in Poland. AIDS Research and Human Retroviruses, 2013, 29, 805-813.	0.5	18
88	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. Lancet HIV,the, 2014, 1, e41-e48.	2.1	17
89	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	1.3	17
90	Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. Aids, 2008, 22, 1943-1950.	1.0	16

#	Article	IF	Citations
91	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 2012, 54, 111-118.	2.9	16
92	Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 15-21.	0.9	16
93	The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels. Aids, 2015, 29, 1355-1361.	1.0	16
94	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. Clinical Infectious Diseases, 2020, 71, 2905-2916.	2.9	16
95	Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm3. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 202-205.	0.9	15
96	Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 100-108.	0.9	15
97	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. Aids, 2011, 25, 1041-1049.	1.0	14
98	HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013 - March 2014. PLoS ONE, 2015, 10, e0137062.	1.1	14
99	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. Aids, 2018, 32, 327-335.	1.0	13
100	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIVâ€positive individuals. Statistics in Medicine, 2019, 38, 2428-2446.	0.8	13
101	Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART). Open AIDS Journal, 2008, 2, 3-9.	0.1	13
102	A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England. BMJ Open, 2017, 7, e016494.	0.8	12
103	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 311-318.	0.9	12
104	Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration. PLoS ONE, 2013, 8, e71174.	1.1	12
105	AIDS defining diseases in the UK: the impact of PCP prophylaxis and twelve years of change. International Journal of STD and AIDS, 1996, 7, 252-257.	0.5	11
106	Rates and Determinants of Virologic and Immunological Response to HAART Resumption After Treatment Interruption in HIV-1 Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 492-498.	0.9	11
107	Virological remission after antiretroviral therapy interruption in female African HIV seroconverters. Aids, 2019, 33, 185-197.	1.0	11
108	Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. Clinical Investigation, 2012, 2, 255-264.	0.0	10

#	Article	IF	Citations
109	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV,the, 2017, 4, e251-e259.	2.1	10
110	A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations. Clinical Infectious Diseases, 2017, 65, 1127-1135.	2.9	10
111	HIV Incidence Estimates Using the Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014. PLoS ONE, 2016, 11, e0157179.	1.1	10
112	2010 Guidelines for Antiretroviral Treatment of HIV From the International AIDS Societyâ€“USA Panel. JAMA - Journal of the American Medical Association, 2010, 304, 1897.	3.8	9
113	Molecular epidemiology of recent HIVâ€1 infections in southern Poland. Journal of Medical Virology, 2012, 84, 1857-1868.	2.5	9
114	Development and future directions for the Joint United Nations Programme on HIV/AIDS estimates. Aids, 2014, 28, S411-S414.	1.0	9
115	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. Aids, 2016, 30, 879-888.	1.0	9
116	Relating HIV testing patterns in Poland to risky and protective behaviour. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 423-431.	0.6	9
117	Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection. PLoS ONE, 2013, 8, e78642.	1.1	9
118	An appraisal of indicators used to monitor the treated population in antiretroviral programmes in low-income countries. Aids, 2010, 24, 2603-2607.	1.0	8
119	Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure. PLoS ONE, 2013, 8, e75608.	1.1	8
120	Evaluating medical conferences: the emerging need for a quality metric. Scientometrics, 2020, 122, 759-764.	1.6	8
121	Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antiviral Therapy, 2007, 12, 189-93.	0.6	8
122	Routine surveillance data on AIDS and HIV infections in the UK: a description of the data available and their use for short-term planning. Epidemiology and Infection, 1988, 100, 157-169.	1.0	7
123	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 314-320.	0.9	6
124	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2862-2868.	1.3	5
125	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. Aids, 2019, 33, 327-337.	1.0	5
126	Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 391-396.	0.9	4

#	Article	IF	Citations
127	Men and the young are key to reaching the first 90. Lancet HIV,the, 2017, 4, e479-e480.	2.1	4
128	Mean Corpuscular Volume as a Marker for Adherence to Zidovudine-Containing Therapy in HIV-Infected Adults. Open AIDS Journal, 2012, 6, 45-52.	0.1	4
129	Setting Up a Standardized Peripheral Blood Mononuclear Cells Processing Laboratory to Support Multi-center HIV/AIDS Vaccine and Intervention Trials. Laboratory Medicine, 2011, 42, 711-718.	0.8	3
130	Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. Antiviral Therapy, 2012, 17, 1039-1048.	0.6	3
131	Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Aids, 1998, 12, 1353-1360.	1.0	2
132	Short-Course Antiretroviral Therapy in Primary HIV Infection. New England Journal of Medicine, 2013, 368, 2036-2037.	13.9	2
133	High Percentage of Recent HIV Infection Leading to Onward Transmission in Odessa, Ukraine Associated with Young Adults. AIDS and Behavior, 2014, 18, 411-418.	1.4	2
134	The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK. PLoS ONE, 2015, 10, e0132772.	1.1	2
135	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 102-109.	0.9	2
136	AIDS AND HEALTH-CARE WORKERS. Lancet, The, 1987, 329, 223-224.	6.3	1
137	Using incidence assays within the context of the recent infections testing algorithm. Aids, 2014, 28, 2167.	1.0	1
138	Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load. Virus Evolution, 2022, 8, veac022.	2.2	1
139	Evaluating the systems used to monitor HIV populations accessing therapy and care in low-income and lower-middle-income countries. Aids, 2012, 26, S137-S145.	1.0	0
140	Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversionâ€”Reply. JAMA Internal Medicine, 2013, 173, 475.	2.6	0